Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 18
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Cardiol Therapeutics Inc
CRDL
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.10
-0.05
-4.35%
Dern. MÀJ: Oct 16, 5:12 PM
$1.10
-0.0476
-4.14%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Comparer
Options
Rapport sur les stocks
Privacy Manager
Cardiol Therapeutics Financials
Cardiol Therapeutics (CRDL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last
Benzinga Newsdesk
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
PRO
Cardiol Therapeutics Q4 EPS $(0.09) Beats $(0.12) Estimate
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from
Benzinga Newsdesk
PRO
Cardiol Therapeutics' Cash And Cash Equivalents Of $34.9M As Of December 31, 2023, Which Funds Operations Into 2026
Benzinga Newsdesk
Mid-Morning Market Update: Markets Mostly Lower; CVS Health Tops Q3 Views
Following the market opening Wednesday, the Dow traded down 0.31% to 35,939.39 while the NASDAQ fell 0.01% to 15,649.42. The S&P also fell, dropping 0.15% to 4,623.92.
Lisa Levin
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Shanthi Rexaline
